Epigenetics Diagnostics Market Report 2025

The epigenetics diagnostics market size has grown rapidly in recent years. It will grow from $14.2 billion in 2024 to $16.56 billion in 2025 at a compound annual growth rate (CAGR) of 16.6%. The growth during the historic period can be attributed to increased research funding for epigenetic studies, expansion of government initiatives, a rising aging population, higher prevalence of neurological disorders, and a growing number of clinical trials.

The epigenetics diagnostics market size is expected to see rapid growth in the next few years. It will grow to $30.29 billion in 2029 at a compound annual growth rate (CAGR) of 16.3%. The growth during the forecast period can be attributed to rising demand for personalized and precision medicine, increasing adoption of liquid biopsy procedures, and growing preference for non-invasive diagnostic methods. Major trends in this period include technological advancements in diagnostics, innovations in liquid biopsy, whole-genome bisulfite sequencing, application of deep learning for biomarker discovery, and integration with personalized medicine approaches.

The increasing demand for personalized medicine is expected to drive the growth of the epigenetics diagnostics market in the coming years. Personalized medicine is an approach that tailors medical treatment to an individual’s genetic makeup, biology, and lifestyle factors. This demand is rising due to advancements in genetic and molecular profiling, which enable therapies customized to a person’s unique biological characteristics, improving treatment efficacy while reducing side effects. Epigenetics diagnostics supports personalized medicine by identifying individual epigenetic patterns, which inform customized prevention and treatment strategies for optimal patient outcomes. For example, in February 2024, the Personalized Medicine Coalition, a US-based non-profit organization, reported that the FDA approved 16 novel personalized therapies for patients with rare diseases in 2023, compared to six in 2022. Therefore, the growing demand for personalized medicine is propelling the expansion of the epigenetics diagnostics market.

Key players in the epigenetics diagnostics market are focusing on developing innovative approaches, such as clinical-grade epigenetic analysis, to improve the accuracy, sensitivity, and clinical utility of detecting disease-related epigenetic modifications. Clinical-grade epigenetic analysis involves using validated and standardized methods to detect epigenetic changes with the precision required for clinical diagnosis and treatment decisions. For instance, in October 2024, EpiMedTech, a Singapore-based biotechnology company, launched epiGeneComplete, a clinical-grade test combining genetic and epigenetic analysis via next-generation sequencing and advanced DNA methylation techniques. The test provides detailed insights into key health indicators, including aging, stress, inflammation, addiction risk, and metabolism. Conducted in CAP-accredited laboratories, this non-invasive saliva-based test offers high sensitivity and accuracy, supports personalized health profiling, and serves as an adaptable platform for future diagnostic expansion, representing a significant advancement in routine health screening and early disease detection.

In January 2023, Agilent Technologies Inc., a US-based biotechnology company, acquired Avida Biomed for an undisclosed amount. This acquisition aims to enhance Agilent’s product portfolio by providing advanced next-generation sequencing tools for clinical research and diagnostics, particularly to accelerate progress in precision oncology and cancer treatment. Avida Biomed, based in the US, specializes in epigenetics diagnostics, focusing on DNA methylation analysis for liquid biopsies.

Major players in the epigenetics diagnostics market are F. Hoffmann-La Roche Ltd., Merck KGaA, Thermo Fisher Scientific Inc., Agilent Technologies Inc., Illumina Inc., PerkinElmer Inc., Bio-Rad Laboratories Inc., QIAGEN N.V., GeneTex Inc., Bio-Techne Corporation, Promega Corporation, New England Biolabs Incorporated, Pacific Biosciences of California Inc., Enzo Biochem Inc., Diagenode Société Anonyme, Zymo Research Corporation, Active Motif Inc., ADmit Therapeutics SL, Epigentek Group Inc., and INHERENT Biosciences Inc.

North America was the largest region in the epigenetics diagnostics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in epigenetic diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the epigenetic diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The fast surge in U.S. tariffs and the trade tensions that followed in spring 2025 are heavily affecting the medical equipment sector, particularly for imported imaging machine components, surgical-grade stainless steel, and plastic disposables. Hospitals and clinics resist price hikes, pressuring manufacturers’ margins. Regulatory hurdles compound the problem, as tariff-related supplier changes often require re-certification of devices, delaying time-to-market. Companies are mitigating risks by dual-sourcing critical parts, expanding domestic production of commoditized items, and accelerating R&D in cost-efficient materials.

Epigenetic diagnostics refers to the scientific approach of detecting and analyzing modifications in gene activity - such as DNA methylation or histone alterations - that do not change the underlying DNA sequence but can significantly impact biological functions. This process focuses on identifying molecular changes to understand how they regulate gene expression and contribute to biological variability.

The primary products in epigenetic diagnostics include kits and reagents, software and services, and instruments. Kits and reagents are specialized tools for studying and analyzing epigenetic modifications such as DNA methylation, histone modifications, and chromatin interactions. These products employ technologies including DNA methylation analysis, histone methylation and acetylation, large noncoding RNA, microRNA modifications, and chromatin structure assessments. Applications span oncology, metabolic diseases, developmental biology, immunology, cardiovascular diseases, and more. Key end users include pharmaceutical and biotechnology companies, academic and research institutions, and clinical diagnostic laboratories.

The epigenetics diagnostics market research report is one of a series of new reports that provides epigenetics diagnostics market statistics, including epigenetics diagnostics industry global market size, regional shares, competitors with an epigenetics diagnostics market share, detailed epigenetics diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the epigenetics diagnostics industry. This epigenetics diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The epigenetic diagnostics market consists of revenues earned by entities by providing services such as histone modification analysis, biomarker discovery, disease risk assessment, single-cell epigenetic analysis, longitudinal epigenetic monitoring, and DNA methylation profiling. The market value includes the value of related goods sold by the service provider or included within the service offering. The epigenetic diagnostics market also includes sales of instruments, sample preparation tools, workflow control kits, and liquid biopsy assays. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.